Peripheral Intervention was Merit Medical Systems’s largest product and service line in fiscal 2025, bringing in $579.84M of $1.52B (38%).
| Product and Service | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peripheral Intervention | $439.81M | $483.27M | $532.77M | $579.84M | ||||||||||||
| Cardiac Intervention | $343.19M | $356.65M | $368.95M | $448.91M | ||||||||||||
| Custom Procedural Solutions | $190.19M | $193.72M | $200.03M | $209.33M | ||||||||||||
| Oem | $145.03M | $186.93M | $199.99M | $204.96M | ||||||||||||
| Stand-Alone Devices | — | — | — | — | ||||||||||||
| Stand Alone Devices | — | — | — | — | ||||||||||||
| Custom Kits & Procedure Trays | — | — | — | — | ||||||||||||
| Custom Kit & Procedures Trays | — | — | — | — | ||||||||||||
| Catheters | — | — | — | — | ||||||||||||
| Inflation Devices | — | — | — | — | ||||||||||||
| Crm/Ep | — | — | — | — | ||||||||||||
| Embolization Devices | — | — | — | — | ||||||||||||
| Endoscopy Devices | $32.76M | $36.81M | $54.77M | $72.86M | ||||||||||||
| Electrophysiology | — | — | — | — | ||||||||||||
| Total | $1.15B | $1.26B | $1.36B | $1.52B |
Merit Medical Systems brought in $1.52B from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 11.8% from $1.36B in fiscal 2024. Peripheral Intervention was the largest at $579.84M (38.3%), ahead of Cardiac Intervention at $448.91M (29.6%) and Custom Procedural Solutions at $209.33M (13.8%). The other two lines brought in $277.82M combined.
Compared with fiscal 2024, Endoscopy Devices grew fastest, up 33.0% to $72.86M. Every line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.15B to $1.52B, a compound annual growth rate of 9.6%. Peripheral Intervention's share held steady at about 38.3%.
United States was Merit Medical Systems’s largest region in fiscal 2025, bringing in $909.47M of $1.52B (60%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $650.56M | $726.99M | $800.78M | $909.47M | ||||||
| International | $500.42M | $530.40M | $555.73M | $606.44M | ||||||
| Total | $1.15B | $1.26B | $1.36B | $1.52B |
Merit Medical Systems brought in $1.52B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 11.8% from $1.36B in fiscal 2024. United States was the largest at $909.47M (60.0%), ahead of International at $606.44M (40.0%).
Compared with fiscal 2024, United States grew 13.6% to $909.47M and International grew 9.1% to $606.44M. From fiscal 2022 to 2025, combined revenue from these regions grew from $1.15B to $1.52B, a compound annual growth rate of 9.6%. United States' share of the total rose from 56.5% to 60.0%.
Cardiovascular was Merit Medical Systems’s largest segment in fiscal 2025, bringing in $1.44B of $1.52B (95%).
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $1.12B | $1.22B | $1.30B | $1.44B | ||||||||||||
| Endoscopy | $32.76M | $36.81M | $54.77M | $72.86M | ||||||||||||
| Total | $1.15B | $1.26B | $1.36B | $1.52B |
Merit Medical Systems brought in $1.52B from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 11.8% from $1.36B in fiscal 2024. Cardiovascular was the largest at $1.44B (95.2%), ahead of Endoscopy at $72.86M (4.8%).
Compared with fiscal 2024, Endoscopy grew 33.0% to $72.86M and Cardiovascular grew 10.9% to $1.44B. From fiscal 2022 to 2025, combined revenue from these segments grew from $1.15B to $1.52B, a compound annual growth rate of 9.6%. Cardiovascular's share of the total fell from 97.2% to 95.2%.
Merit Medical Systems (MMSI) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Peripheral Intervention was its largest product and service line, bringing in $579.84M (38.3% of the total), followed by Cardiac Intervention at $448.91M (29.6%).
Peripheral Intervention was Merit Medical Systems' largest product and service line in fiscal 2025, bringing in $579.84M, or 38.3% of the $1.52B total across its five product and service lines.
United States was Merit Medical Systems' largest region in fiscal 2025, bringing in $909.47M, or 60.0% of the $1.52B total across its two regions.
Cardiovascular was Merit Medical Systems' largest segment in fiscal 2025, bringing in $1.44B, or 95.2% of the $1.52B total across its two segments.
Among Merit Medical Systems' product and service lines that make up at least 2% of revenue, Endoscopy Devices grew fastest in fiscal 2025, up 33.0% from $54.77M to $72.86M.
Every figure comes from Merit Medical Systems' annual financial filings, as reported. Each line keeps the name Merit Medical Systems gives it, and years follow its fiscal calendar.
Merit Medical Systems' revenue by product and service goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.